Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells.
Anders W MatsonRob HullsiekKate J DixonSam WangAnders J LindstedtRyan R FriessShee Kwan PhungTanya S FreedmanMartin FelicesEmily N TruckenbrodJianming WuJeffrey S MillerBruce WalcheckPublished in: Journal for immunotherapy of cancer (2024)
Our data reveal for the first time that CD16A and CD137 underpin Medi-1 enhancement of IL-15-driven NK cell activation and proliferation, respectively, with the latter requiring PBMC accessory cells. The use of Medi-1 represents a novel strategy to enhance IL-15-driven NK cell proliferation, and it may be of therapeutic importance by increasing the antitumor activity of NK cells in patients with cancer.